[Biological therapies in systemic lupus erythematosus]

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Context:

• Systemic lupus erythematosus (SLE) management relies on immunosuppressive agents with significant but non-specific effects.
• Existing treatments necessitate the development of more targeted therapies with improved safety profiles.
• Advances in understanding autoimmune disease mechanisms drive innovation in therapeutic strategies.

Purpose:

• To review the development and application of biologic therapies for systemic lupus erythematosus (SLE).
• To highlight novel therapeutic targets including B cell depletion, co-stimulation blockade, and cytokine inhibition.
• To evaluate the efficacy of anti-CD20 monoclonal antibodies in refractory SLE cases.

Summary:

• Biologic therapies represent a new frontier in SLE treatment, targeting specific immune components.
• Anti-CD20 monoclonal antibodies demonstrate promising results in patients resistant to conventional therapies.
• These targeted approaches offer potential for improved disease control and reduced adverse effects.

Impact:

• Biologic therapies provide a viable treatment option for patients with refractory SLE.
• These advancements hold promise for the future management of SLE, potentially altering long-term patient outcomes.
• The development of targeted immunosuppression signifies a shift towards personalized medicine in autoimmune diseases.